gold stock

Dear Reader,

At no point in the history of the world has the interest on money been so low as it is now.

Who can dispute the good Sen. Henry M. Teller of Colorado?

For lo eight years, the Federal Reserve has waged a ceaseless warfare upon interest rates.

Economic law, history, logic itself, stagger under the onslaughts.

We suspect that economic reality will one day prevail.

This fear haunts our days and poisons our nights.

But let us check the date on the senators declaration

Kind heaven, can it be?

We are reliably informed that Sen. Tellers comment entered the congressional minutes on Jan. 12 1895.

1895 some 19 years before the Federal Reserve drew its first ghastly breath!

Were interest rates 122 years ago the lowest in world history?

And are low interest rates the historical norm… rather than the exception?

Today we rise above the daily churn… canvass the broad sweep of history and pursue the grail of truth.

gold stock: State Bank Financial Corporation.(STBZ)

Advisors’ Opinion:

  • [By Zacks]

    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
     
    J P Morgan Chase & Co (NYSE: JPM): Free Stock Analysis Report
     
    Comerica Incorporated (NYSE: CMA): Free Stock Analysis Report
     
    Wells Fargo & Company (NYSE: WFC): Free Stock Analysis Report
     
    Citigroup Inc. (NYSE: C): Free Stock Analysis Report
     
    Wintrust Financial Corporation (NASDAQ: WTFC): Free Stock Analysis Report
     
    Synovus Financial Corp. (NYSE: SNV): Free Stock Analysis Report
     
    State Bank Financial Corporation. (NASDAQ: STBZ): Free Stock Analysis Report
     
    To read this article on Zacks.com click here.
     
    Zacks Investment Research

gold stock: Haynes International, Inc.(HAYN)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Wednesday, basic materials shares fell by 1.24 percent. Meanwhile, top losers in the sector included Haynes International, Inc. (NASDAQ: HAYN), down 12 percent, and McEwen Mining Inc (NYSE: MUX), down 9 percent.

  • [By Lisa Levin]

    In trading on Tuesday, basic materials shares fell 0.44 percent. Meanwhile, top losers in the sector included Haynes International, Inc. (NASDAQ: HAYN), down 5 percent, and Gibraltar Industries Inc (NASDAQ: ROCK), down 4 percent.

  • [By Lisa Levin]

    Basic materials sector was the top gainer in the US market on Monday. Top gainers in the sector included Haynes International, Inc. (NASDAQ: HAYN), Cliffs Natural Resources Inc (NYSE: CLF), and Olympic Steel, Inc. (NASDAQ: ZEUS).

gold stock: Werner Enterprises, Inc.(WERN)

Advisors’ Opinion:

  • [By Michael Flannelly]

    Following Werner Enterprises, Inc.’s (WERN) third quarter earnings warning, analysts at KeyBanc downgraded the transportation and logistics company on Tuesday.

    The analysts downgraded WERN from “Buy” to “Hold.”

    KeyBanc analyst Todd Fowler said, “We downgrade WERN from Buy to HOLD following its negative 3Q pre-ann’ct, which reflected a number of company-specific issues that we expect to limit upside going forward; we would focus investors on other, stronger-performing names within the truckload space, specifically, BUY-rated Swift Transportation Company (SWFT), Marten Transport Ltd. (MRTN), and Knight Transportation Inc. (KNX).”

    Werner Enterprises shares were down $1.66, or 6.80%, during pre-market trading on Tuesday. The stock is up 12.64% year-to-date.

  • [By Monica Gerson]

    Werner Enterprises (NASDAQ: WERN) issued a weak third-quarter profit forecast. Werner shares dropped 2.09% to $23.90 in the after-hours trading session.

  • [By Monica Gerson]

    Werner Enterprises (NASDAQ: WERN) shares dropped 4.83% to $23.23 in pre-market trading after the company issued a weak third-quarter profit forecast.

  • [By Jake L’Ecuyer]

    Equities Trading DOWN
    Shares of Outerwall (NASDAQ: OUTR) were down 16.03 percent to $47.00 after the company lowered its forecast for the third quarter and full year. Werner Enterprises (NASDAQ: WERN) shares tumbled 4.71 percent to $23.26 after the company issued a weak third-quarter profit forecast. Bank of America downgraded the stock from Buy to Neutral. Pandora Media (NYSE: P) down, falling 1.71 percent to $23.58 as the company announced its plans to sell 14 million shares of common stock, including 4 million shares from current stockholders.

gold stock: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Cory Renauer]

    Treating diseases that have a genetic component by altering the expression of the responsible genes is a promising new field of medicine, but it has been much less straightforward than biopharmaceutical companies had expected. Two contenders in this area, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS), saw a mix of setbacks and success in 2016.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) jumped as much as 14.5% today after announcing earnings after the bell yesterday. As a development-stage biotech, it wasn’t the revenue or the earnings that caused the spike, but the progression of Allnylam’s pipeline.

  • [By Lisa Levin]

    Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares shot up 53 percent to $114.87 after the company impressed investors with encouraging data from a phase 3 clinical trial. Alnylam, a company dedicated towards treating a wide range of debilitating diseases through ribonucleic acid (RNA) interference (RNAi) therapeutics, said after Tuesday's market close that a phase 3 study called APOLLO met its primary efficacy endpoint and all secondary endpoints.

  • [By Chris Dier-Scalise]

    On Thursday, the Vetr crowd downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from 4.5 stars (Strong Buy), which was issued two days ago, to 3.5 stars (Hold). Crowd sentiment for Alnylam at the time of the downgrade was edging positive, with 66 percent of Vetr user rating bullish.

  • [By Ben Levisohn]

    Yesterday, after markets closed, it was announced that US Federal District Court Judge Sue Robinson ruled to issue a permanent injunction against Praluent, the PCSK9 mAb for hypercholesterolemia from partners Regeneron and Sanofi, due to infringement of patents from Amgen. The court has imposed a 30-day suspension (stay) on the injunction to allow for settlement or appeal of the District Court decision. Sanofi and Regeneron have announced their intent to appeal the ruling to the US Court of Appeals for the Federal Circuit (CAFC). The injunction decision is consistent with our counter-consensus published views communicated on 25 January 2016 (“Downgrade to Sell on evidence of likely infringement of Amgen’s PCSK9 patents”) and subsequently. Based on consultation with expert legal counsel, we now put >75% probability Amgen will prevail on appeal and/or Praluent is ultimately removed from the US market, and/or Amgen achieves a settlement substantially in its favor. We currently model $3.3 bn in non-risk-adjusted 2022E US revenues for Praluent, while consensus models $1.2 bn in 2022E US revenues. We reiterate our view from 25 January 2016 to preferentially own Amgen, The Medicines Company (MDCO) (Buy), and Alnylam (ALNY) (Buy) over Regeneron for exposure to PCSK9 inhibitor market dynamics as outcomes trials approach.

Leave a Reply

Your email address will not be published. Required fields are marked *